振东制药2025年度净利预亏2.2亿元—2.8亿元

Core Viewpoint - Zhendong Pharmaceutical (300158) forecasts a net loss attributable to shareholders of the listed company for the fiscal year 2025, estimated between 22 million to 28 million yuan [1] Group 1: Reasons for Performance Change - The company's production and operational activities are normal; however, changes in industry policies and market conditions have led to a decline in sales or prices of certain products, resulting in decreased profit contributions from these products [1] - During the reporting period, the prices of certain traditional Chinese medicine materials continued to decline due to overall market supply and demand dynamics, causing the company's traditional Chinese medicine business to remain in a loss state [1] - It is expected that non-recurring gains and losses will impact the net profit attributable to shareholders by approximately 15 million yuan, primarily from government subsidies and investment income; in the same period last year, the impact of non-recurring gains and losses was -64.222 million yuan [1]